Solid Q1 2025 Fuels Optimism for FY25
09/05/25 -"Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of consensus. All segments and regions contributed to ..."
Pages
51
Language
English
Published on
09/05/25
You may also be interested by these reports :
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...
30/12/25
Over the last three years, GSK’s earnings have exceeded the market’s expectations on most occasions. Moreover, the firm’s R&D efforts have yielded ...
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...